Federal Register Notice: FDA has determined the regulatory review period for Alliance Pharmaceutical Corp.’s Imagent (perfluorohexane and DMPC) is 2,264 days for the extension of a patent which claims that human drug product. Imagent is indicated for use in subjects with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left venricular endocardiol border. To view this notice, click here.
